Evelo Bio grabs $85M as the latest early-stage biotech debuts on Nasdaq
Evelo Biosciences became the latest early-stage biotech company to make the leap into Nasdaq. The Cambridge, MA-based company priced 5.3 million shares at $16 — smack dab in the middle of the range — to add $85 million to its reserves.
The stock will start trading today under the $EVLO symbol, fresh evidence that the market for new biotech stocks continues to have legs in 2018.
The company is helmed by CEO Simba Gill, who’s out to make “monoclonal microbials” into a new drug class. And that’s the kind of story that has been floating dozens of new biotechs over the past 18 months.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
